BIOMARIN PHARMACEUTICAL INC (BMRN) Stock Fundamental Analysis
USA - NASDAQ:BMRN - US09061G1013 - Common Stock
51.46 USD
-0.38 (-0.73%)
51.89 USD
+0.43 (+0.84%)
Taking everything into account, BMRN scores 6 out of 10 in our fundamental rating. BMRN was compared to 531 industry peers in the Biotechnology industry. BMRN scores excellent points on both the profitability and health parts. This is a solid base for a good stock. BMRN scores decently on growth, while it is valued quite cheap. This could make an interesting combination. With these ratings, BMRN could be worth investigating further for value and quality investing!.
1. Profitability
1.1 Basic Checks
BMRN had positive earnings in the past year.
In the past year BMRN had a positive cash flow from operations.
Of the past 5 years BMRN 4 years were profitable.
Each year in the past 5 years BMRN had a positive operating cash flow.
1.2 Ratios
BMRN has a Return On Assets of 6.83%. This is amongst the best in the industry. BMRN outperforms 92.35% of its industry peers.
Looking at the Return On Equity, with a value of 8.59%, BMRN belongs to the top of the industry, outperforming 92.91% of the companies in the same industry.
BMRN has a better Return On Invested Capital (7.69%) than 93.47% of its industry peers.
The Average Return On Invested Capital over the past 3 years for BMRN is significantly below the industry average of 15.48%.
The 3 year average ROIC (3.73%) for BMRN is below the current ROIC(7.69%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.83% | ||
| ROE | 8.59% | ||
| ROIC | 7.69% |
ROA(3y)3.59%
ROA(5y)4.88%
ROE(3y)4.67%
ROE(5y)6.69%
ROIC(3y)3.73%
ROIC(5y)N/A
1.3 Margins
BMRN has a better Profit Margin (16.82%) than 94.22% of its industry peers.
With an excellent Operating Margin value of 20.21%, BMRN belongs to the best of the industry, outperforming 94.59% of the companies in the same industry.
With an excellent Gross Margin value of 81.32%, BMRN belongs to the best of the industry, outperforming 85.26% of the companies in the same industry.
In the last couple of years the Gross Margin of BMRN has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 20.21% | ||
| PM (TTM) | 16.82% | ||
| GM | 81.32% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.25%
GM growth 5Y0.19%
2. Health
2.1 Basic Checks
BMRN has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for BMRN has been increased compared to 1 year ago.
Compared to 5 years ago, BMRN has more shares outstanding
BMRN has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 5.00 indicates that BMRN is not in any danger for bankruptcy at the moment.
The Altman-Z score of BMRN (5.00) is better than 75.00% of its industry peers.
The Debt to FCF ratio of BMRN is 0.72, which is an excellent value as it means it would take BMRN, only 0.72 years of fcf income to pay off all of its debts.
BMRN's Debt to FCF ratio of 0.72 is amongst the best of the industry. BMRN outperforms 94.96% of its industry peers.
BMRN has a Debt/Equity ratio of 0.10. This is a healthy value indicating a solid balance between debt and equity.
BMRN has a worse Debt to Equity ratio (0.10) than 63.99% of its industry peers.
Even though the debt/equity ratio score it not favorable for BMRN, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.1 | ||
| Debt/FCF | 0.72 | ||
| Altman-Z | 5 |
ROIC/WACC0.94
WACC8.2%
2.3 Liquidity
BMRN has a Current Ratio of 4.83. This indicates that BMRN is financially healthy and has no problem in meeting its short term obligations.
BMRN's Current ratio of 4.83 is in line compared to the rest of the industry. BMRN outperforms 52.80% of its industry peers.
BMRN has a Quick Ratio of 3.10. This indicates that BMRN is financially healthy and has no problem in meeting its short term obligations.
BMRN's Quick ratio of 3.10 is on the low side compared to the rest of the industry. BMRN is outperformed by 61.01% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.83 | ||
| Quick Ratio | 3.1 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 52.00% over the past year.
Looking at the last year, BMRN shows a quite strong growth in Revenue. The Revenue has grown by 12.39% in the last year.
BMRN shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 10.86% yearly.
EPS 1Y (TTM)52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-129.09%
Revenue 1Y (TTM)12.39%
Revenue growth 3Y15.62%
Revenue growth 5Y10.86%
Sales Q2Q%4.08%
3.2 Future
The Earnings Per Share is expected to grow by 27.59% on average over the next years. This is a very strong growth
Based on estimates for the next years, BMRN will show a small growth in Revenue. The Revenue will grow by 7.34% on average per year.
EPS Next Y37.42%
EPS Next 2Y42.81%
EPS Next 3Y33.39%
EPS Next 5Y27.59%
Revenue Next Year12.45%
Revenue Next 2Y9.95%
Revenue Next 3Y9.2%
Revenue Next 5Y7.34%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
BMRN is valuated rather expensively with a Price/Earnings ratio of 19.35.
Based on the Price/Earnings ratio, BMRN is valued cheaper than 94.78% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.06, BMRN is valued a bit cheaper.
BMRN is valuated reasonably with a Price/Forward Earnings ratio of 11.42.
BMRN's Price/Forward Earnings ratio is rather cheap when compared to the industry. BMRN is cheaper than 97.20% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 32.73, BMRN is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.35 | ||
| Fwd PE | 11.42 |
4.2 Price Multiples
BMRN's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. BMRN is cheaper than 95.52% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of BMRN indicates a rather cheap valuation: BMRN is cheaper than 97.57% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.97 | ||
| EV/EBITDA | 12.39 |
4.3 Compensation for Growth
BMRN's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of BMRN may justify a higher PE ratio.
A more expensive valuation may be justified as BMRN's earnings are expected to grow with 33.39% in the coming years.
PEG (NY)0.52
PEG (5Y)N/A
EPS Next 2Y42.81%
EPS Next 3Y33.39%
5. Dividend
5.1 Amount
No dividends for BMRN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
51.46
-0.38 (-0.73%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners98.83%
Inst Owner Change1.16%
Ins Owners0.65%
Ins Owner Change1.95%
Market Cap9.88B
Revenue(TTM)3.09B
Net Income(TTM)520.42M
Analysts83.53
Price Target95.71 (85.99%)
Short Float %4.47%
Short Ratio4.18
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-48.87%
Min EPS beat(2)-142.18%
Max EPS beat(2)44.44%
EPS beat(4)3
Avg EPS beat(4)-11.96%
Min EPS beat(4)-142.18%
Max EPS beat(4)44.44%
EPS beat(8)6
Avg EPS beat(8)2.48%
EPS beat(12)9
Avg EPS beat(12)14.79%
EPS beat(16)12
Avg EPS beat(16)-9.32%
Revenue beat(2)1
Avg Revenue beat(2)1.98%
Min Revenue beat(2)-2.53%
Max Revenue beat(2)6.48%
Revenue beat(4)2
Avg Revenue beat(4)1.32%
Min Revenue beat(4)-2.53%
Max Revenue beat(4)6.48%
Revenue beat(8)4
Avg Revenue beat(8)1.53%
Revenue beat(12)5
Avg Revenue beat(12)0.37%
Revenue beat(16)7
Avg Revenue beat(16)0.03%
PT rev (1m)-1.71%
PT rev (3m)-2.04%
EPS NQ rev (1m)12.82%
EPS NQ rev (3m)5.53%
EPS NY rev (1m)-13.82%
EPS NY rev (3m)-13.73%
Revenue NQ rev (1m)1.06%
Revenue NQ rev (3m)-0.93%
Revenue NY rev (1m)-0.03%
Revenue NY rev (3m)0.87%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.35 | ||
| Fwd PE | 11.42 | ||
| P/S | 3.19 | ||
| P/FCF | 11.97 | ||
| P/OCF | 10.81 | ||
| P/B | 1.63 | ||
| P/tB | 1.76 | ||
| EV/EBITDA | 12.39 |
EPS(TTM)2.66
EY5.17%
EPS(NY)4.51
Fwd EY8.76%
FCF(TTM)4.3
FCFY8.36%
OCF(TTM)4.76
OCFY9.25%
SpS16.11
BVpS31.54
TBVpS29.31
PEG (NY)0.52
PEG (5Y)N/A
Graham Number43.45
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.83% | ||
| ROE | 8.59% | ||
| ROCE | 9.17% | ||
| ROIC | 7.69% | ||
| ROICexc | 9.82% | ||
| ROICexgc | 10.68% | ||
| OM | 20.21% | ||
| PM (TTM) | 16.82% | ||
| GM | 81.32% | ||
| FCFM | 26.69% |
ROA(3y)3.59%
ROA(5y)4.88%
ROE(3y)4.67%
ROE(5y)6.69%
ROIC(3y)3.73%
ROIC(5y)N/A
ROICexc(3y)4.34%
ROICexc(5y)N/A
ROICexgc(3y)4.77%
ROICexgc(5y)N/A
ROCE(3y)4.44%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.25%
GM growth 5Y0.19%
F-Score8
Asset Turnover0.41
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.1 | ||
| Debt/FCF | 0.72 | ||
| Debt/EBITDA | 0.84 | ||
| Cap/Depr | 106.6% | ||
| Cap/Sales | 2.85% | ||
| Interest Coverage | 85.91 | ||
| Cash Conversion | 129.08% | ||
| Profit Quality | 158.68% | ||
| Current Ratio | 4.83 | ||
| Quick Ratio | 3.1 | ||
| Altman-Z | 5 |
F-Score8
WACC8.2%
ROIC/WACC0.94
Cap/Depr(3y)111.01%
Cap/Depr(5y)114.82%
Cap/Sales(3y)4.71%
Cap/Sales(5y)5.6%
Profit Quality(3y)57.85%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-129.09%
EPS Next Y37.42%
EPS Next 2Y42.81%
EPS Next 3Y33.39%
EPS Next 5Y27.59%
Revenue 1Y (TTM)12.39%
Revenue growth 3Y15.62%
Revenue growth 5Y10.86%
Sales Q2Q%4.08%
Revenue Next Year12.45%
Revenue Next 2Y9.95%
Revenue Next 3Y9.2%
Revenue Next 5Y7.34%
EBIT growth 1Y52.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year97.49%
EBIT Next 3Y41.32%
EBIT Next 5Y23.21%
FCF growth 1Y2529.91%
FCF growth 3Y36.9%
FCF growth 5YN/A
OCF growth 1Y559.43%
OCF growth 3Y23.45%
OCF growth 5Y63.99%
BIOMARIN PHARMACEUTICAL INC / BMRN FAQ
Can you provide the ChartMill fundamental rating for BIOMARIN PHARMACEUTICAL INC?
ChartMill assigns a fundamental rating of 6 / 10 to BMRN.
Can you provide the valuation status for BIOMARIN PHARMACEUTICAL INC?
ChartMill assigns a valuation rating of 8 / 10 to BIOMARIN PHARMACEUTICAL INC (BMRN). This can be considered as Undervalued.
Can you provide the profitability details for BIOMARIN PHARMACEUTICAL INC?
BIOMARIN PHARMACEUTICAL INC (BMRN) has a profitability rating of 7 / 10.
What is the expected EPS growth for BIOMARIN PHARMACEUTICAL INC (BMRN) stock?
The Earnings per Share (EPS) of BIOMARIN PHARMACEUTICAL INC (BMRN) is expected to grow by 37.42% in the next year.